Palisade Bio (Nasdaq: PALI) to Present at the Biocom Global Life Science Partnering Conference
February 18 2022 - 8:30AM
Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage
biopharmaceutical company advancing therapies for acute and chronic
gastrointestinal (GI) complications, will present at the Biocom
Global Life Science Partnering Conference in San Diego on Thursday,
February 24, 2022. Palisade Bio’s Chief Executive Officer, Tom
Hallam, Ph.D., is scheduled to present an updated presentation at
11:30 a.m. Pacific Time. Palisade Bio’s presentation can be
accessed at on our website at www.palisadebio.com/investors.
“Palisade Bio’s near-term focus is to develop our product
candidate, LB1148, our lead asset advancing towards global
Phase 3 studies for return to bowel function after GI surgery. I am
thrilled to present at the Biocom conference and provide an update
on our key milestones and review the significant progress we’ve
made as a company,” stated Tom Hallam, CEO of Palisade Bio.
The 12th Annual Global Life Science Partnering Conference is
returning in-person to The Lodge at Torrey Pines in February 2022.
This conference is an exclusive global partnering forum that brings
together senior executives, bankers, venture capitalists, and
business development professionals from leading pharmaceutical and
biotech companies.
About Palisade Bio
Palisade Bio is a clinical stage biopharmaceutical company
advancing therapies that help patients with acute and chronic
gastrointestinal complications stemming from post-operative
digestive enzyme damage. Palisade Bio’s innovative lead asset
LB1148, advancing towards Phase 3, is a protease inhibitor with the
potential to both reduce abdominal adhesions and help restore bowel
function following surgery. Positive data from Phase 2 trials of
LB1148 demonstrated safety and tolerability as well as a
statistically significant improvement in return to bowel function
and decrease in length of stay in ICU and hospital compared to
placebo. Palisade Bio believes that its investigational therapies
have the potential to address the myriad health conditions and
complications associated with chronic disruption of the
gastrointestinal epithelial barrier. For more information, please
go to www.palisadebio.com.
Forward Looking StatementsThis communication
contains “forward-looking” statements, including, without
limitation, statements related to expectations regarding Palisade’s
plans for future presentations at investor conferences. Any
statements contained in this communication that are not statements
of historical fact may be deemed to be forward-looking statements.
These forward-looking statements are based upon Palisade’s current
expectations. Forward-looking statements involve risks and
uncertainties. Palisade’s actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, the Company’s
ability to advance its clinical programs and the uncertain and
time-consuming regulatory approval process. Additional risks and
uncertainties can be found in Palisade Bio’s Quarterly Report on
Form 10-Q for the quarter ended September 30, 2021. Palisade
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in Palisade’s expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statements are based.
Palisade Bio Investor Relations Contact:Dawn
Hofmeisterir@palisadebio.com
Palisade Bio Media Relations Contact:CORE
IRJules Abrahamjulesa@coreir.com917-885-7378
Palisade Bio (NASDAQ:PALI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Palisade Bio (NASDAQ:PALI)
Historical Stock Chart
From Jul 2023 to Jul 2024